Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran.
Amirhossein
A
Sahebkar
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001384:Azetidines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008297:Male; D043484:Proprotein Convertases / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D000924:Anticholesteremic Agents; D001384:Azetidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D043484:Proprotein Convertases